🔴 Moleculin Biotech is trading 5% down; no clear company-specific catalyst identified

Moleculin Biotech is trading at $0.46, down 5.14%, with no clear company-specific catalyst identified for the October 5 decline.

• The latest reported company announcement was September 29: enrollment in Part A of its MIRACLE trial was completed, with a data readout planned for Q1 2027.
• The supplied major-index snapshot is mixed and does not establish a broader-market explanation for the decline.